Weekly Digest - October 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - October 2024
30 Sep 2024: Alphamab Oncology and CSPC enter licensing agreement for Anti-HER2 bispecific ADC JSKN003
- Alphamab Oncology announced a licensing agreement for the anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 with JMT-Bio Technology, a subsidiary of CSPC Pharmaceutical Group
- Under the agreement, JMT-Bio gains exclusive rights to develop, sell, and commercialize JSKN003 for tumor-related indications in mainland China, excluding Hong Kong, Macau, and Taiwan
- Alphamab will receive an upfront payment of RMB 400 million, with potential milestone payments totaling up to RMB 3.08 billion, including royalties on net sales
- JSKN003 was developed using Alphamab’s proprietary conjugation platform, showing better serum stability and efficacy in clinical trials involving heavily pretreated patients with advanced solid tumors
